Sort   by:  
 Page size 
TranscriptomicsGene expression profiles of nurse-like cells (NLCs) generated in vitro from chronic lymphocytic leukemia in presence of lenalidomide
NLCs were generated in vitro by culturing PBMCs from CLL patients for 10 days with/without the addition of 0.5 µM lenalidomide. Then, nonadherent cells were removed by vigorous pipetting and the remaining adherent cells were harvested for analyses. We inspected the whole-genome gene expression prof...
ORGANISM(S): Homo sapiens 
2014-11-24 | E-GEOD-57861 | biostudies-arrayexpress
ProteomicsLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Science 2014, 343, 301-305. doi:10.1126/science.1244851. Lenalidomide is a drug with clinical efficacy in multiple myeloma an...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2015-01-26 | MSV000079017 | MassIVE
ProteomicsLenalidomide-induced pure red cell aplasia analysis
The RVd therapy, combining lenalidomide, bortezomib, and dexamethasone, is a mainstay treatment for multiple myeloma. A multiple myeloma patient developed pure red cell aplasia (PRCA) following RVd treatment, despite the absence of common PRCA triggers. In vitro analyses revealed lenalidomide as a p...
ORGANISM(S): Homo Sapiens 
PXD055495 |
GenomicsCC-122 versus Lenalidomide
CC-122 versus Lenalidomide
PRJNA474537 | ENA
GenomicsEffect of Lenalidomide on human macrophages.
Effect of Lenalidomide on human macrophages.
PRJNA694117 | ENA
TranscriptomicsImpact of Gene Expression Profiling Based Risk Stratification in Patients with Myeloma Receiving Initial Therapy with Lenalidomide and Dexamethasone
Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma (MM); however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of two GEP-based risk stratification...
ORGANISM(S): Homo sapiens 
2011-08-25 | E-GEOD-31504 | biostudies-arrayexpress
TranscriptomicsDexamethasone and lenalidomide have distinct functional effects on erythropoiesis
We explored the effects of dexamethasone and lenalidomide, individually and in combination, on the differentiation of primary human bone marrow progenitor cells in vitro. Both agents promote erythropoiesis, increasing the absolute number of erythroid cells produced from normal CD34+ cells and from ...
ORGANISM(S): Homo sapiens 
2011-04-28 | E-GEOD-28896 | biostudies-arrayexpress
GenomicsRNASeq: lenalidomide-treated anti-BCMA CAR T cells
RNASeq: lenalidomide-treated anti-BCMA CAR T cells
PRJNA450645 | ENA
GenomicsATACSeq - human CAR-T cells treated with lenalidomide
ATACSeq - human CAR-T cells treated with lenalidomide
PRJNA454267 | ENA
TranscriptomicsAffymetrix SNP array data for myelodysplastic syndrome with 5q deletion treated with lenalidomide
Lenalidome is a drug especially effective in low risk myelodysplastic syndromes (MDS) with isolated 5q deletion. However, 25% of the patients did not respond. TP53 mutations have been described to play a role in the disease progression, and karyotypic complexity also has an important impact in the o...
ORGANISM(S): Homo sapiens 
2013-07-01 | E-GEOD-35656 | biostudies-arrayexpress
Sort   by:  
 Page size